Skip to main content
PLOS One logoLink to PLOS One
. 2024 Mar 14;19(3):e0298642. doi: 10.1371/journal.pone.0298642

Intensity scaling of conventional brain magnetic resonance images avoiding cerebral reference regions: A systematic review

Tun Wiltgen 1,2,*, Cuici Voon 1,2, Koen Van Leemput 3,4, Benedikt Wiestler 5, Mark Mühlau 1,2,*
Editor: Md Nasir Uddin6
PMCID: PMC10939249  PMID: 38483873

Abstract

Background

Conventional brain magnetic resonance imaging (MRI) produces image intensities that have an arbitrary scale, hampering quantification. Intensity scaling aims to overcome this shortfall. As neurodegenerative and inflammatory disorders may affect all brain compartments, reference regions within the brain may be misleading. Here we summarize approaches for intensity scaling of conventional T1-weighted (w) and T2w brain MRI avoiding reference regions within the brain.

Methods

Literature was searched in the databases of Scopus, PubMed, and Web of Science. We included only studies that avoided reference regions within the brain for intensity scaling and provided validating evidence, which we divided into four categories: 1) comparative variance reduction, 2) comparative correlation with clinical parameters, 3) relation to quantitative imaging, or 4) relation to histology.

Results

Of the 3825 studies screened, 24 fulfilled the inclusion criteria. Three studies used scaled T1w images, 2 scaled T2w images, and 21 T1w/T2w-ratio calculation (with double counts). A robust reduction in variance was reported. Twenty studies investigated the relation of scaled intensities to different types of quantitative imaging. Statistically significant correlations with clinical or demographic data were reported in 8 studies. Four studies reporting the relation to histology gave no clear picture of the main signal driver of conventional T1w and T2w MRI sequences.

Conclusions

T1w/T2w-ratio calculation was applied most often. Variance reduction and correlations with other measures suggest a biologically meaningful signal harmonization. However, there are open methodological questions and uncertainty on its biological underpinning. Validation evidence on other scaling methods is even sparser.

1 Introduction

Conventional T1-weighted (T1w) and T2-weighted (T2w) magnetic resonance imaging (MRI) have been used in clinical settings since the early days of MRI. The development of these sequences primarily aimed at high tissue contrast to aid visual inspection. In other words, conventional MRI sequences are optimized for high local contrast rather than for consistency of intensity values over the scan volume or over time. The absolute intensity values of T1w and T2w images can indeed vary largely due to several technical factors (e.g., MR hardware, amplifier gain, patient anatomy); they also have an arbitrary scale. Thus, intensity-based quantitative analysis of T1w or T2w images is not easily feasible. However, intensity variations of conventional MRI also contain biologically meaningful signals. For example, myelin maturation during brain development is perfectly paralleled by the T1w signal change in humans [1, 2], which has been confirmed histologically in pigs [3]. Therefore, intensity scaling of conventional MRI presents an attractive candidate to convert images with highly variable intensities with arbitrary scales into images with semi-quantitative intensity values, making it possible to analyze intensity variations of conventional MRI for biological questions. Given the broad use of conventional brain MRI, valid methods for intensity scaling could be easily translated into clinical practice and applied for the analyses of large-scale scientific databases. An essential prerequisite is the bias field correction, which removes local intensity inhomogeneities within MR images. Particularly, in studies investigating image intensities, local intensity inhomogeneities induced by transmit and receiver field inhomogeneities should be removed through bias field correction because observed signal variations (after intensity scaling) should arise from biological differences of tissues rather than from technical factors. Bias field correction has been established as a pre-processing step in many image processing pipelines (e.g., SPM) [4]. Although it reduces technically induced local intensity variance, it cannot harmonize arbitrary intensity scales and remove inter-scan variability.

Scaling conventional bias-corrected MRI can be achieved by histogram matching or scaling according to the overall mean image intensity [59]. The use of a biologically defined reference region, such as white matter or normal-appearing parts of it [10], constitutes an intuitive approach. The rationale is that a reference region, assumed to have equal biological properties across all subjects, should, in theory, lead to the same MRI signal, given that no technically induced variance exists. Hence, simple linear scaling according to the reference region should remove the technically induced intensity variance while preserving biologically meaningful variance. A reference region within the brain seems reasonable in circumscribed pathologies such as neoplasms, but it does not seem reasonable in systemic degenerative or inflammatory disorders since disease-related effects may even change the biological properties of the reference region, whose properties are no longer the same across subjects with varying disease burden. For example, in Multiple Sclerosis (MS), the entire brain can be affected, and even the normal-appearing white matter (on MRI) already shows histological changes [11], demonstrating the importance of avoiding cerebral reference regions, which can be liable candidates in these cases.

Originally, we planned to include studies using an extracerebral reference region for intensity scaling. However, the literature search revealed many studies that applied intensity scaling without reference regions but by using the T1w/T2w-ratio introduced by Glasser and van Essen [12]. We found several versions of this approach, either with or without prior scaling of the T1w and T2w images with extracerebral reference regions. Hence, we decided to extend the scope of our review and included studies using the T1w/T2w-ratio with or without prior intensity scaling if the validity of the approach was investigated. Calculation of T1w/T2w-ratio images does not require a reference region, and by dividing T1w by T2w image intensities, it is possible to obtain images with new contrasts. Most of these studies assume that the ratio of T1w and T2w images reflects myelin [12], since voxels in highly myelinated regions have high-intensity values in T1w images but low-intensity values in T2w images, but did not evaluate the method further. In addition, it has been hypothesized that T1w and T2w images are similarly affected by technical artifacts, such as the receiver bias field (B1-), and that, therefore, by calculating the ratio of T1w and T2w images, these technical artifacts are canceled out at the same time [1214]. Yet, this assumption cannot be made for the transmit bias field (B1+), and does not seem to be true for all MRI scanners; in consequence, some authors suggested separate scaling of T1w and T2w images before calculating the ratio of the two [14].

This systematic review includes original publications on approaches for intensity scaling of conventional T1w and T2w brain MRI without using a cerebral reference region. As the application of a scaling method per se does not provide evidence of the validity of the approach, we defined inclusion criteria requiring analyses of the validity of the scaling method. To be included, studies had to provide comparative data regarding the variance reduction of intensities induced by other scaling methods including brain reference regions (e.g., histogram matching or scaling according to overall mean intensity). In many circumstances, brain reference regions can be a reasonable option for intensity scaling. This enables us to evaluate the performance of scaling methods avoiding brain reference regions. We aimed to analyze if the scaling methods of interest in this review (those avoiding cerebral reference regions) lead to similar variance reduction as established methods. Alternatively, studies had to provide the relation to other imaging techniques or the relation to histology.

2 Materials and methods

This review’s reporting and structure rely on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 (PRISMA 2020) [15]. The main review questions, search strategy, eligibility criteria, and data extraction strategy had been defined beforehand, and a detailed review protocol was registered on PROSPERO [16]. Due to different research questions, heterogeneous selection of analysis, and paradigms between studies, we could not perform a meta-analysis.

We conducted the literature search on 1 November 2022 on the following web databases: Scopus, PubMed, and Web of Science. Our search settings included combinations of the terms “magnetic resonance”, “imag*”, “intensit*”, “normali*”, “brain*”, and combinations of synonyms thereof. The exact settings for each database are presented in Table 1.

Table 1. Literature search settings.

database Search settings
Scopus TITLE-ABS-KEY (((magnetic W/3 resonan*) OR t1* OR mr*) AND imag* AND intensit* AND (calibr* OR quantif* OR normali* OR standardi*) AND (brain* OR head* OR cerebr*))
PubMed (magnetic resonan*[Title/Abstract] OR t1*[Title/Abstract] OR mr*[Title/Abstract]) AND imag*[Title/Abstract] AND intensit*[Title/Abstract] AND (calibr*[Title/Abstract] OR quantif*[Title/Abstract] OR normali*[Title/Abstract] OR standardi*[Title/Abstract]) AND (brain*[Title/Abstract] OR head*[Title/Abstract] OR cerebr* [Title/Abstract])
Web of Science (TS = (((magnetic W/3 resonan*) OR t1 OR t1w OR mr OR mri) AND imag* AND intensit* AND (calibr* OR quantif* OR normali* OR standardi*) AND (brain* OR head* OR cerebr*))) OR (AB = (((magnetic W/3 resonan*) OR t1 OR t1w OR mr OR mri) AND imag* AND intensit* AND (calibr* OR quantif* OR normali* OR standardi*) AND (brain* OR head* OR cerebr*))) OR (AK = (((magnetic W/3 resonan*) OR t1 OR t1w OR mr OR mri) AND imag* AND intensit* AND (calibr* OR quantif* OR normali* OR standardi*) AND (brain* OR head* OR cerebr*))) OR (KP = (((magnetic W/3 resonan*) OR t1 OR t1w OR mr OR mri) AND imag* AND intensit* AND (calibr* OR quantif* OR normali* OR standardi*) AND (brain* OR head* OR cerebr*)))

Table 1 provides a detailed overview of the search settings applied in each database during the literature search. Scopus: TITLE-ABS-KEY indicates that any of the words mentioned thereafter should be included in the title, abstract, or keywords; W/3 indicates that the two words before and after should be located within a 3-word span; OR and AND indicate logical operators; * indicates that the word can have further characters in that specific place. PubMed: every word is followed by [Title/Abstract], which indicates that the word has to appear in the title or the abstract; OR and AND and * have the same role as in Scopus; Web of Science: search settings are defined separately for the title, the abstract, the author keywords, and the keywords plus field.

Abbreviations: ABS/AB: abstract; AK: author keywords; KP: keyword plus field; TS: title.

In addition, we conducted a forward and backward citation search for all the included studies on 5 November 2022 using Web of Science. We specified the eligibility criteria according to the PICO framework during the pre-registration process of the review protocol.

  • (P) Patient Population: Humans, no further restrictions.

  • (I) Intervention (method under investigation): Methods that avoid cerebral reference regions for intensity scaling of conventional T1w and T2w brain MR images.

  • (C) Comparator: As a comparator, we considered other scaling methods (e.g., based on reference regions in the brain), quantitative imaging, MRI measures related to tissue microstructure, or histological examinations.

  • (O) Outcome: Relation to quantitative imaging and MRI measures related to tissue microstructure. Relation to histology. Analysis of magnetic resonance imaging (MRI) intensity variance if comparison to another method was available. Relation to clinical or demographic data, if comparison to another method, to quantitative imaging or MRI measures related to tissue microstructure (such as magnetization transfer ratio), or to histology was available.

Hence, studies were included if they met the following inclusion criteria: human study; conventional T1w or T2w brain MRI; intensity scaling avoiding cerebral reference regions; comparison of scaled intensities with another method, quantitative imaging or MRI measures related to tissue microstructure, or histology; description of scaling method; accessible scientific paper; extractable results. Studies were screened for inclusion by TW and MM, and disagreements were solved through discussion. Risk of Bias was assessed with a customized tool based on the tools provided by Cochrane, QUADAS, and NIH. Further details on the search strategy, selection process, risk of bias assessment, and results reporting methods are presented in S1 File.

3 Results

3.1 Study selection and flow diagram

A detailed PRISMA flow diagram of the selection process is depicted in Fig 1. In total, 3825 studies were included in the title and abstract screening, and 24 finally met the inclusion criteria. Details on exclusions are given in S1 File. The results of Risk of Bias assessment are presented in Fig 2.

Fig 1. PRISMA flow chart.

Fig 1

The flow chart shows each step of the literature screening and the number of studies excluded in each step. After screening, 24 studies remained and were included in this systematic review.

Fig 2. Risk of Bias assessment results.

Fig 2

The Risk of Bias assessment results are presented in detail in (A), and the number of studies per rating category for each risk of bias item is depicted in (B). In both figures, green fields indicate a low risk of bias, yellow fields indicate some concerns, and red fields indicate a high risk of bias.

3.2 Study characteristics

The characteristics of the 24 included studies are summarized in Table 2. Most studies focused on the scaling of T1w images (including T1w/T2w-ratios). The studies on T1w/T2w-ratios calculated the ratio either without or with scaling of the T1w or T2w images beforehand. We will refer to these approaches as either “unscaled” or “scaled” T1w/T2w-ratio. We refer to “unscaled” ratios whenever image intensities have not been scaled. However, images used to calculate the ratio may have undergone bias field correction as in most studies using T1w/T2w-ratios (Table 3 in S1 File). Only one study investigated the scaling of T2w images exclusively [17] and two studies the scaling of independent T2w and T1w images [18, 19]. Given the low number of studies and the heterogenous methodology, the results on scaling T2w images are included in the tables but will not be considered further. The included studies largely focused on MR images of healthy people but also included images of people with MS (also post-mortem), people with monophasic demyelinating disorders, people with Alzheimer’s disease, people with lower-grade glioma, people with Glioblastoma, and children born preterm. The scaling methods applied in the included studies also differed. In total, seven different scaling methods were applied. Most studies implemented the method proposed by Ganzetti et al. [14], which uses the median intensity values of extracerebral reference regions (eyeball and temporal muscle) to scale T1w and T2w image intensities before calculating the T1w/T2w-ratio:

sIGanzetti=XR-YRXS-YS*I+XSYR-XRYSXS-YS

with X: median (temporal muscle), Y: median (eyeball), R: template image, S: subject image. Some studies also calculated T1w/T2w-ratio, but they did not scale T1w and T2w images beforehand. The studies by Brown et al. [20] and Gilmore et al. [18] scaled intensities by dividing the conventional MR-image intensities by the median intensity of orbital fat and by the mean intensity of subcutaneous fat, respectively. Soun et al. [21] followed the method of Ganzetti et al. [14] but they used the masseter muscle instead of the temporal muscle. The study by Loizou et al. [17] used the matlab function ‘gscale’ and histogram normalization.

Table 2. Study characteristics.

Study Data Source #Subjects Age Health Status / Disorder Imaging Modalities Reference Region(s) Scaling Method
Arshad et al. 2017 [23] In-house 20 Mean = 45.9 years HC T1w, T2w, MWF, geomT2IEW eyeballs, temporal muscle sI(Ganzetti)
Brown et al. 2020 [20] In-house 179 5-20 years HC, MS, monophasic demyelinating disorders T1w, MTR orbital fat sI(Brown)
Cappelle et al. 2022 [22] In-house 207 Mean = 40.65 years MS T1w, T2w, FLAIR, MTR eyeballs, temporal muscle sI(Ganzetti) (T1w/T2w and T1w/FLAIR)
Ganzetti et al. 2014 [14] (a)
(b)
63 Mean = 31.97 years HC T1w, T2w, FLAIR, MTR, FA eyeballs, temporal muscle sI(Ganzetti)
Gilmore et al. 2007 [18] In-house 47 Mean = 39.7 weeks gestational age HC T1w, T2w, DWI (FA, MD) subcutaneous fat sI(Gilmore)
Hagiwara et al. 2018 [24] In-house 20 Mean = 55.3 years HC SyMRI Data (T1w, T2w, MVF, MTsat) eyeballs, temporal muscle sI(Ganzetti)
Hannoun et al. 2022 [25] In-house 52 Mean = 36.1 years HC, MS T1w, T2w, DWI eyeballs, temporal muscle sI(Ganzetti)
Loizou et al. 2009 [17] In-house 32 Mean = 30.75 years HC, MS T2w CSF, air from sinuses Matlab function gscale, Histogram Normalization
Luo et al. 2019 [26] (c) 252 Mean = 73.76 years HC, preclinical AD, prodromal AD, AD dementia T1w, T2w, FLAIR, PET imaging eyeballs, temporal muscle sI(Ganzetti)
Nakamura et al. 2017 [27] In-house 6 Mean = 62.5 years MS (post-mortem) T1w, T2w, MTR T1w/T2w-ratio
Pareto et al. 2020 [28] In-house 22 Mean = 41.13 years MS T1w, T2w, MTR T1w/T2w-ratio
Preziosa et al. 2021 [45] In-house 25 Mean = 67.0 years HC, MS T1w, T2w, FLAIR
(histology)
eyeballs, temporal muscle sI(Ganzetti)
Righart et al. 2017 [46] In-house In-vivo: 248
Post-mortem: 9
Mean(in-vivo) = 30.8 years
Mean(post-mortem) = 65.9 years
HC, MS, MS (post-mortem) T1w, T2w, FLAIR
(histology)
T1w/T2w-ratio
Saccenti et al. 2020 [29] In-house 21 Mean = 37.9 years MS SyMRI Data (T1w, T2w, MVF, MTsat)
DWI
eyeballs, temporal muscle sI(Ganzetti)
Sanada et al. 2022 [30] (d) 163 Lower-grade Glioma T1w, T2w, T1-relaxometry, T2-relaxometry eyeballs, temporal muscle sI(Ganzetti)
Shams et al. 2019 [31] In-house 17 Mean = 24.7 years HC T1w, T2w, T1-relaxometry T1w/T2w-ratio
Shim et al. 2022 [32] In-house 10 Mean = 32.7 years HC T1w, T2*w, T1-relaxometry, T2-relaxometry T1w/T2*w-ratio
Soun et al. 2017 [21] In-house 10 Mean = 38.7 weeks gestational age HC T1w, T2w, FLAIR, DWI eyeballs, masseter muscle sI(Soun)
Uddin et al. 2018 [19] In-house 10 Mean = 57.1 years MS T1w, T2w, GRASE (MWF) eyeballs, temporal muscle sI(Ganzetti)
Uddin et al. 2019 [33] In-house 31 Mean = 29.6 years HC T1w, GRASE (T2w, MWF), DWI eyeballs, temporal muscle sI(Ganzetti)
Vandewouw et al. 2019 [34] In-house 56 Mean = 4.3 years 4-year-old children (born very preterm, born full term) T1w, T2w, MTR T1w/T2w-ratio
Yamamoto et al. 2022 [35] In-house 34 Mean = 63.5 years Glioblastoma T1w, T2w, T1-relaxometry, T2-relaxometry, [11C]Met-PET eyeballs, temporal muscle sI(Ganzetti)
Yasuno et al. 2017 [36] In-house 38 Mean = 70.4 years HC T1w, T2w, PET imaging eyeballs, temporal muscle sI(Ganzetti)
Zheng et al. 2022 [37] In-house 9 Mean = 64.7 years MS (post-mortem) T1w, T2w, MTR
(histology)
T1w/T2w-ratio

Abbreviations: AD: Alzheimer’s disease; DWI: diffusion weighted imaging; FA: fractional anisotropy; FLAIR: fluid-attenuated inversion recovery; geomT2IEW: geometric-mean of the intra-/extracellular water T2; GRASE: gradient and spin echo; HC: healthy controls; MD: mean diffusivity; Met: methionine; MS: multiple sclerosis; MTR: magnetization transfer ratio; MTsat: magnetization transfer saturation; MWF: myelin water fraction; MVF: myelin volume fraction; PET: positron emission tomography.

(a) IXI database of the Imperial College London (http://biomedic.doc.ic.ac.uk/brain-development/index.php?n=Main.Dataset)

(b) KIRBY21 database of the Kirby Research Center for Functional Brain Imaging in Baltimore (http://mri.kennedykrieger.org/databases.html)

(c) Alzheimer’s disease Neuroimaging Initiative database (adni.loni.usc.edu)

(d) In-house & Cancer Imaging Archive/Cancer Genome Atlas low-grade glioma collection dataset (https://www.cancerimagingarchive.net/)

sIBrown=Imedian(orbitalfat) with I: unscaled intensity, sI: scaled intensity

sIGanzetti=XR-YRXS-YS*I+XSYR-XRYSXS-YS with X: median(temporal muscle), Y: median(eyeball), R: template, S: subject

sIGilmore=Imean(subcutaneousfat) with I: unscaled intensity, sI: scaled intensity

sISoun=XR-YRXS-YS*I+XSYR-XRYSXS-YS with X: mean(masseter muscle), Y: mean(eyeball), R: template, S: subject

3.3 Results of individual studies and syntheses

3.3.1 Variance reduction

Four studies investigated variance reduction; an overview of the results is provided in Table 3. In the study by Brown et al. [20], inter-scan variance of T1w images was reduced through scaling with orbital fat but less so when compared to scaling according to normal-appearing white matter (NAWM) through the “White-Stripe” method [7]. The two studies using scaled T1w/T2w-ratios also showed a considerable reduction of inter-scan variance as statistically significant differences between different datasets vanished when scaled T1w/T2w-ratios were used instead of unscaled T1w/T2w-ratios [14]; further, coefficients of variance were reduced for T1w/T2w-ratios and even more so for T1w/FLAIR-ratios by three different scaling methods based on histogram calibration using extracerebral tissue [22].

Table 3. Variance reduction results.
Reference Region Images Comparative Method Variance Assessment ROI before Scaling after Scaling after Comparative Method Removed Variance Scaling equal to or better than Comparative Method
Brown et al. 2020
orbital fat scaled T1w White-Stripe visual histogram inspection Brain large variability low variability low variability
2 peaks for WM 1 peak for WM 1 peak for WM
2 peaks for GM 1 peak for GM 1 peak for GM
intensity range ±estimation error(a) WM 4.5 ±0.3 2 ±0.3 1 ±0.3
GM 3.5 ±0.3 2 ±0.3 0.5 ±0.3
Cappelle et al. 2022
eyeballs, temporal muscle scaled T1w/T2w-ratio nonlinear histogram calibration with generic template Coefficient of Variance (%) NAWM 12.0 13.2 12.1
NAGM 15.1 13.0 11.7
MS Lesions 23.7 20.0 13.5
Corpus Callosum 18.5 18.2# 13.0*+
Thalamus 13.7 13.6 11.0
nonlinear histogram calibration with subject template Coefficient of Variance (%) NAWM 12.0 13.2 9.7
NAGM 15.1 13.0 13.0
MS Lesions 23.7 20.0 17.3
Corpus Callosum 18.5 18.2 13.2
Thalamus 13.7 13.6 10.6
scaled T1w/FLAIR-ratio nonlinear histogram calibration with generic template Coefficient of Variance (%) NAWM 24.0 19.1# 9.5*+
NAGM 26.1 17.0* 12.0*
MS Lesions 27.5 23.0# 9.7*
Corpus Callosum 28.6 24.8# 12.4*
Thalamus 26.5 23.4# 11.7*+
nonlinear histogram calibration with subject template Coefficient of Variance (%) NAWM 24.0 19.1 13.8*
NAGM 26.1 17.0* 15.1*
MS Lesions 27.5 23.0 22.0#
Corpus Callosum 28.6 24.8 18.6*#
Thalamus 26.5 23.4§ 16.5*+
Ganzetti et al. 2014
eyeballs, temporal muscle scaled T1w/T2w-ratio unscaled T1w/T2w-ratio visual histogram inspection Brain different intensity scales similar intensity scales (see before scaling)
large between-dataset and inter-subject variability reduced between-dataset and inter-subject variability (see before scaling)
mean ±sd WM IXI 1.5T: 3.44 ±0.31 IXI 1.5T: 2.11 ±0.15 (see before scaling)
IXI 3T: 4.52 ±0.82 IXI 3T: 2.04 ±0.10 (see before scaling)
KIRBY21 3T: 28.49 ±4.63 KIRBY21 3T: 2.07 ±0.14 (see before scaling)
ANOVA (difference between datasets) WM p<0.001 p = 0.2236 (see before scaling)
Loizou et al. 2009
sinus air, CSF scaled T2w (intensity scaling) contrast stretch and normalization Kullback Leibler Divergence Distance(b) (mean ±sd) Brain intra-scan: 0.336 ±0.130 intra-scan: 0.112 ±0.00 intra-scan: 0.156 ±0.01
inter-scan: 0.406 ±0.135 inter-scan: 0.250 ±0.017 inter-scan: 0.247 ±0.015
histogram stretching intra-scan: 0.336 ±0.130 intra-scan: 0.112 ±0.00 intra-scan: 0.178 ±0.020
inter-scan: 0.406 ±0.135 inter-scan: 0.250 ±0.017 inter-scan: 0.298 ±0.023
gaussian kernel normalization intra-scan: 0.336 ±0.130 intra-scan: 0.112 ±0.00 intra-scan: 0.165 ±0.00
inter-scan: 0.406 ±0.135 inter-scan: 0.250 ±0.017 inter-scan: 0.290 ±0.010
histogram equalization intra-scan: 0.336 ±0.130 intra-scan: 0.112 ±0.00 intra-scan: 0.185 ±0.010
inter-scan: 0.406 ±0.135 inter-scan: 0.250 ±0.017 inter-scan: 0.287 ±0.006
scaled T2w (histogram normalization) contrast stretch and normalization Kullback Leibler Divergence Distance(b) (mean ±sd) Brain intra-scan: 0.336 ±0.130 intra-scan: 0.099 ±0.00 intra-scan: 0.156 ±0.01
inter-scan: 0.406 ±0.135 inter-scan: 0.142 ±0.010 inter-scan: 0.247 ±0.015
histogram stretching intra-scan: 0.336 ±0.130 intra-scan: 0.099 ±0.00 intra-scan: 0.178 ±0.020
inter-scan: 0.406 ±0.135 inter-scan: 0.142 ±0.010 inter-scan: 0.298 ±0.023
gaussian kernel normalization intra-scan: 0.336 ±0.130 intra-scan: 0.099 ±0.00 intra-scan: 0.165 ±0.00
inter-scan: 0.406 ±0.135 inter-scan: 0.142 ±0.010 inter-scan: 0.290 ±0.010
histogram equalization intra-scan: 0.336 ±0.130 intra-scan: 0.099 ±0.00 intra-scan: 0.185 ±0.010
inter-scan: 0.406 ±0.135 inter-scan: 0.142 ±0.010 inter-scan: 0.287 ±0.006

Table 3 summarizes data on variance reduction for eligible studies. For each result, we indicated if the scaling method in question removed variance and whether it removed more or less variance than the comparative method. Abbreviations: ANOVA: analysis of variance; CSF: cerebrospinal fluid; FLAIR: fluid attenuated inversion recovery; GM: gray matter; MS: multiple sclerosis; NAWM/NAGM: normal-appearing white/gray matter; NLG: nonlinear histogram calibration with generic template; NLS: nonlinear histogram calibration with subject template; Sd: standard deviation; ROI: region(s) of interest; WM: white matter.

Statistically significant difference with unscaled ratio: *, statistically significant difference with scaled ratio (Ganzetti): +, statistically significant difference with NLG-scaled: #; statistically significant difference with NLS-scaled: §.

(a): We visually estimated the intensity ranges (given in standardized intensity units) from the intensity histograms because no value was provided by the authors. The values should, therefore, be considered with an error of +/-0.3 due to possible inaccuracies in the extraction process.

(b): intra-scan Kullback Leibler Divergence (KLD) Distance was calculated between different slices from the same scan, and inter-scan KLD Distance was calculated between corresponding slices from different scans (i.e., corresponding slices of original images and scaled images)

3.3.2 Relation to quantitative imaging and MRI measures related to tissue microstructure

Twenty studies investigated relationships between scaled images and quantitative imaging [14, 1837]. In total, scaled images were compared to 16 quantitative imaging methods (Fig 3). Detailed results summaries are shown in Table 4 (scaled T1w images, scaled T2w images, unscaled T1w/T2w-ratio) and Table 5 (scaled T1w/T2w-ratio). Although we are aware that they are not fully quantitative, we refer to the “MRI measures related to tissue microstructure”, such as magnetization transfer ratio (MTR) or diffusion-weighted imaging (DWI), as “quantitative imaging” for readability.

Fig 3. Availability of quantitative imaging and MRI measures related to tissue microstructure.

Fig 3

This histogram shows the number of studies having investigated each quantitative imaging technique (with multiple counts regarding studies because they might have compared multiple quantitative sequences). Abbreviations: AD: axial diffusivity; ADC: apparent diffusion coefficient; AV: amyvid; DWI: diffusion weighted imaging; FA: fractional anisotropy; FDG: fluorodeoxyglucose; MD: mean diffusivity; MTR: magnetization transfer ratio; MTsat: magnetization transfer saturation; MVF: myelin volume fraction; MWF: myelin water fraction; PET: positron emission tomography; PiB: Pittsburgh compound B; RD: radial diffusivity.

Table 4. Relation between scaled T1w, scaled T2w, and unscaled T1w/T2w-ratio images and quantitative imaging or MRI measures related to tissue microstructure.
Reference Region(s) Quantitative Sequence ROI #Scans Results Significance
Scaled T1w
Brown et al. 2020
orbital fat MTR brain 650 0.63 (positive) NA
Gilmore et al. 2007
subcutaneous fat FA genu (central) 47 no correlation
genu (cortical) 47 no correlation
splenium (central) 47 no correlation
splenium (cortical) 47 no correlation
corticospinal tract (central) 47 no correlation
corticospinal tract (cortical) 47 no correlation
MD genu (central) 47 no correlation
genu (cortical) 47 no correlation
splenium (central) 47 no correlation
splenium (cortical) 47 0.1602 (negative) **
corticospinal tract (central) 47 no correlation
corticospinal tract (cortical) 47 no correlation
Uddin et al. 2018
eyeballs, temporal muscle MWF WM 10 0.006 (positive)
subcortical GM 10 0.15 (positive) *
brain 10 0.056 (positive) **
Scaled T2w
Gilmore et al. 2007
CSF FA genu (central) 47 negative *
genu (cortical) 47 negative *
splenium (central) 47 negative *
splenium (cortical) 47 negative *
corticospinal tract (central) 47 negative *
corticospinal tract (cortical) 47 negative *
MD genu (central) 47 positive *
genu (cortical) 47 positive *
splenium (central) 47 positive *
splenium (cortical) 47 positive *
corticospinal tract (central) 47 positive *
corticospinal tract (cortical) 47 positive *
Uddin et al. 2018
eyeballs, temporal muscle MWF WM 10 0.048 (positive) *
subcortical GM 10 0.23 (positive) **
brain 10 0.12 (positive) ***
Unscaled T1w/T2w
Nakamura et al. 2017
MTR cortical regions 6 0.194 (positive) **
Shams et al. 2019
T1 relaxometry (R1) cortical regions 17 0.74 (positive) NA
Shim et al. 2022
q-ratio (R1/T2*) WM 10 0.4833 (positive) ***
GM 10 0.819 (positive) ***
Vandewouw et al. 2019
MTR WM 56 0.33 (positive) ***
subcortical GM 56 0.77 (positive) ***
cortical GM 56 0.25 (positive) ***
Pareto et al. 2020
MTR NAWM 22 0.631 (positive) **
NAGM 22 0.502 (positive) *
MS-lesions 22 0.699 (positive) **
CSF 22 0.631 (positive) *

Table 4 summarizes relations between scaled T1w, scaled T2w, and unscaled T1w/T2w-ratio images and quantitative imaging. The “Results” column shows the quantified relation in terms of R2 values derived from linear regression, with an indication of negative or positive correlation. All correlations were calculated across subjects using mean intensities from indicated regions of interest. Abbreviations: CSF: cerebrospinal fluid; FA: fractional anisotropy; GM: gray matter; MD: mean diffusivity; MS: multiple sclerosis; MTR: magnetization transfer ratio; MWF: myelin water fraction; NA: not available/applicable; NAWM/NAGM: normal-appearing; ROI: region of interest; WM: white matter.

*: p<0.05,

**: p<0.01,

***: p<0.001

Table 5. Relation between scaled T1w/T2w-ratios and quantitative imaging or MRI measures related to tissue microstructure.
Reference Region(s) Quantitative Sequence ROI #Scans Results p-Value Comparison Metric Voxel-level (VL) / Region-level (RL) Correlation
Arshad et al. 2017
eyeballs, temporal muscle MWF WM 20 0.068 (negative) * R2, linear regression RL
geomT2IEW WM 20 0.292 (negative) * R2, linear regression RL
Soun et al. 2017
eyeballs, masseter muscle ADC PLIC & optic radiation 10 0.96 (positive) *** R2, linear regression VL
Uddin et al. 2018
eyeballs, temporal muscle MWF WM 10 0.00002 (positive) R2, linear regression RL
Subcortical GM 10 0.2 (positive) ** R2, linear regression RL
Brain 10 0.053 (positive) ** R2, linear regression RL
Uddin et al. 2019
eyeballs, temporal muscle MWF WM 31 0.061 (positive) + R2, linear regression RL
Subcortical GM 31 0.060 (positive) + R2, linear regression RL
Brain 31 0.106 (positive) + R2, linear regression RL
FA WM 31 0.002 (positive) R2, linear regression RL
Subcortical GM 31 0.082 (positive) + R2, linear regression RL
Brain 31 0.060 (positive) + R2, linear regression RL
AD WM 31 0.003 (negative) R2, linear regression RL
Subcortical GM 31 0.116 (positive) + R2, linear regression RL
Brain 31 0.021 (positive) + R2, linear regression RL
RD WM 31 0.005 (positive) R2, linear regression RL
Subcortical GM 31 0.012 (positive) R2, linear regression RL
Brain 31 0.005 (positive) R2, linear regression RL
MD WM 31 0.002 (negative) R2, linear regression RL
Subcortical GM 31 0.023 (positive) R2, linear regression RL
Brain 31 0.001 (negative) R2, linear regression RL
Yamamoto et al. 2022
eyeballs, temporal muscle T1 relaxometry non-enhancing tumor 2 0.002 (negative) * R2, linear regression VL
T2 relaxometry non-enhancing tumor 2 0.067 (negative) * R2, linear regression VL
Sanada et al. 2022
eyeballs, temporal muscle T1 relaxometry lower-grade glioma 8 0.64 (negative) NA R2, exponential regression VL
T2 relaxometry lower-grade glioma 8 0.59 (negative) NA R2, exponential regression VL
Hagiwara et al. 2018
eyeballs, temporal muscle MVF WM 20 0.450 *** Spearman rho VL
Subcortical GM 20 0.690 *** Spearman rho VL
Cortical GM 20 0.750 *** Spearman rho VL
Brain 20 0.870 *** Spearman rho VL
MTsat WM 20 0.380 *** Spearman rho VL
Subcortical GM 20 0.680 *** Spearman rho VL
Cortical GM 20 0.540 *** Spearman rho VL
Brain 20 0.800 *** Spearman rho VL
Saccenti et al. 2020
eyeballs, temporal muscle MVF NAWM 21 0.500 *** Spearman rho RL
Plaque (MS) 21 0.780 *** Spearman rho RL
Periplaque (MS) 21 0.620 *** Spearman rho RL
NAWM+plaque+periplaque 21 0.890 *** Spearman rho RL
MTsat NAWM 21 0.280 * Spearman rho RL
Plaque (MS) 21 0.640 *** Spearman rho RL
Periplaque (MS) 21 0.410 *** Spearman rho RL
NAWM+plaque+periplaque 21 0.800 *** Spearman rho RL
RD NAWM 21 0.110 Spearman rho RL
Plaque (MS) 21 -0.580 *** Spearman rho RL
Periplaque (MS) 21 -0.090 Spearman rho RL
NAWM+plaque+periplaque 21 -0.660 *** Spearman rho RL
Yasuno et al. 2017
eyeballs, temporal muscle [11C]PiB-PET Orbital frontal cortex 38 0.210 Spearman rho RL
Lateral prefrontal cortex 38 0.240 Spearman rho RL
Medial prefrontal cortex 38 0.540 *** Spearman rho RL
Anterior cingulate cortex 38 0.250 Spearman rho RL
Medial frontal cortex 38 0.490 *** Spearman rho RL
Cortex 38 0.450 ** Spearman rho RL
Hannoun et al. 2022
eyeballs, temporal muscle FA 16/24 WM ROIs 52 range: 0.37–0.54 * Spearman rho RL
AD 8/24 WM ROIs 52 range: -0.51–0.50 * Spearman rho RL
RD 18/24 WM ROIs 52 range: -0.73–(-0.38) * Spearman rho RL
Luo et al. 2019
eyeballs, temporal muscle [18F]FDG PET Right inferior parietal lobule 252 NA r, partial correlation RL
Left inferior parietal lobule 252 NA r, partial correlation RL
Right hippocampus 252 0.380 *** r, partial correlation RL
Left hippocampus 252 0.400 * r, partial correlation RL
[18F]AV-45 PET Right inferior parietal lobule 252 no correlation r, partial correlation RL
Left inferior parietal lobule 252 no correlation r, partial correlation RL
Right hippocampus 252 0.430 * r, partial correlation RL
Left hippocampus 252 0.410 * r, partial correlation RL
Ganzetti et al. 2014
eyeballs, temporal muscle MTR Brain 21 similar trend & amplitude change NA comparison of t-scores RL
FA Brain 21 similar trend & different amplitude change NA comparison of t-scores RL

Table 5 summarizes data on relations between scaled T1w/T2w-ratio images and quantitative imaging. The “Results” column shows the quantified relation in terms of R2 values derived from linear regression, R2 values derived from exponential regression, Spearman rho, r from partial correlations, or comparison of t-scores, with an indication of negative or positive correlation. All correlations were calculated across subjects using mean intensities from regions of interest, indicated as region-level, or using intensities from voxels, indicated as voxel-level. Abbreviations: AD: axial diffusivity; ADC: apparent diffusion coefficient; AV: amyvid; FA: fractional anisotropy; FDG: fluorodeoxyglucose; GM: gray matter; MD: mean diffusivity; MS: multiple sclerosis; MTR: magnetization transfer ratio; MTsat: magnetization transfer saturation; MVF: myelin volume fraction; MWF: myelin water fraction; NA: not available/applicable; NAWM: normal-appearing white matter; PET: positron emission tomography; PiB: Pittsburgh compound B; PLIC: posterior limb of the internal capsule; RD: radial diffusivity; ROI: region(s) of interest; WM: white matter.

*: p<0.05,

**: p<0.01,

***: p<0.001,

+: p<0.000001 (Bonferroni corrected)

Scaled T1w images. The strongest correlations were found with magnetization transfer ratio (MTR), which has been found to be sensitive to myelin, tissue integrity, and axonal counts [3841]. Brown et al. [20] reported a strong positive relation (R2 = 0.63) with MTR across the brain. Statistically significant positive correlations were also observed with myelin water fraction (MWF), a histologically validated myelin marker [40, 4244], in subcortical grey matter (GM) regions of interest (ROIs) (R2 = 0.15, p<0.05) but not in white matter (WM) ROIs [19]. The correlations with DWI metrics, known to be sensitive to microstructural changes, were statistically insignificant, except for the correlation between mean diffusivity (MD) and scaled T1w image intensities in the ‘cortical splenium’ (R2 = 0.16, p<0.01) [18].

Unscaled T1w/T2w-ratio. In three studies, unscaled T1w/T2w-ratios were compared to MTR values, and they all found statistically significant positive correlations. Statistically significant positive correlations of different strengths were observed in WM (R2 = 0.33, p<0.001), subcortical GM (R2 = 0.77, p<0.001), and cortical GM (R2 = 0.25, p<0.001) [34], in NAWM (R2 = 0.63, p<0.01), normal-appearing grey matter (NAGM) (R2 = 0.50, p<0.05), MS-lesions (R2 = 0.70, p<0.01), and cerebrospinal fluid (CSF) (R2 = 0.63, p<0.05) [28], and in cortical regions (R2 = 0.19, p<0.01) [27]. In two studies, strong correlations were reported with T1 relaxation rate (R1) in cortical regions [31] (R2 = 0.8) and with relaxometry-based “q-ratio” values (q-ratio = R1/T2*) in WM (R2 = 0.48, p<0.001) as well as in GM (R2 = 0.82, p<0.001) [32].

Scaled T1w/T2w-ratio. Two studies assessed the relation to MTR values only qualitatively. A positive relation of MTR values with scaled T1w/T2w-ratios [14, 22] and scaled T1w/FLAIR-ratios [22] was described.

Correlations with DWI were weak and inconsistent. No congruent results were observed with radial diffusivity (RD) as correlations were reported to be statistically significant [25] or insignificant [29], [33] in WM regions; in MS WM lesions correlations were statistically significant (Spearman rho = -0.58, p<0.001) [29]; in subcortical GM, no statistically significant correlations were observed [33]. Correlations with DWI fractional anisotropy (FA) were also inconsistent since they were statistically significant [25] or insignificant [33] in WM, and statistically significant correlations were found in GM [14, 33]. Likewise, correlations with axial diffusivity (AD) were statistically significant in subcortical GM (R2 = 0.12, p<0.000001 Bonferroni corrected) [33] but, in WM, statistically insignificant, negative, or positive [25, 33]. No statistically significant correlation was observed with MD [33], and a statistically significant positive correlation with the apparent diffusion coefficient (ADC) was found in the posterior limb of the internal capsule and in the optic radiation (R2 = 0.96, p<0.001) [21].

Surprisingly, three studies found differing results on correlations with MWF and reported statistically significant negative (R2 = 0.07, p<0.05) [23] or positive (R2 = 0.06–0.11) [33] correlations in healthy people as well as statistically significant positive and insignificant correlations [19] in people with MS.

Correlations with multi-echo T2-based geometric-mean of the intra-/extracellular water T2 (geomT2IEW) values, which are supposed to be sensitive to the diameter of axons, were statistically significant (negative) in WM of healthy people (R2 = 0.29, p<0.05) [23].

Negative correlations of scaled T1w/T2w-ratios with T1- and T2-relaxation times were found within lower-grade glioma (T1-ralaxation: R2 = 0.64; T2-relaxation: R2 = 0.59) [30] and within non-contrast-enhancing glioblastoma lesions (T1-relaxation: R2 = 0.002; T2-relaxation: R2 = 0.07) [35].

Using synthetic MRI data, two studies found statistically significant positive correlations between scaled T1w/T2w-ratios and myelin volume fraction (MVF) (Spearman rho = 0.45–0.89), assumed to measure the amount of myelin per voxel, and with magnetization transfer saturation (MTsat) (Spearman rho = 0.28–0.80), assumed to be sensitive to microstructural integrity, across various brain regions [24, 29]. Notice that in these two studies, the conventional T1w and the T2w images were estimated from SyMRI multiparameter mapping, and resulting intensities were subsequently scaled and used for T1w/T2w-ratio calculation.

3.3.3 Relation to clinical or demographical data

Eight studies used scaled images to investigate group differences (e.g., healthy controls vs. people with MS) or the relation of scaled image intensities with clinical or demographical data [18, 20, 25, 26, 28, 29, 34, 45].

Scaled T1w image intensities correlated with age at onset and disease duration for monophasic acquired demyelinating syndrome and MS, similar to MTR values [20], but no coherent trend was observed for scaled T1w image intensities and DWI-metrics (FA and MD) in their correlation with gestational age [18].

Unscaled T1w/T2w-ratios and MTR values did not correlate with gestational age but with development assessment in WM, whereas, in this regard, only T1w/T2w-ratio correlated in cortical GM and MTR in subcortical GM [34]. Correlations with Expanded Disability Status Scale (EDSS) were similar for unscaled T1w/T2w-ratios and MTR values, but only unscaled T1w/T2w-ratios showed statistically significant negative correlations with disease duration within MS WM lesions [28].

Scaled T1w/T2w-ratios in WM were statistically significantly decreased in people with MS (compared to healthy people), which went along with a statistically significant decrease in FA, an increase in AD, and an increase in RD [25]. In contrast to the results on unscaled T1w/T2w-ratios [28], scaled T1w/T2w-ratios based on synthetic MRI did not statistically significantly correlate with EDSS and with disease duration [29].

3.3.4 Relation to histology

Four studies related scaled or unscaled T1w/T2w-ratios to histology-based measures [27, 37, 45, 46], these results are summarized in Table 5 in S1 File.

In one study, scaled T1w/T2w-ratios statistically significantly correlated with neurite density, whereas no correlation with myelin density was observed in the cortex [45]. When investigating group differences between healthy people (n = 10) and people with MS (n = 15) in the normal-appearing cortex, statistically significant differences for scaled T1w/T2w-ratios (p = 0.045) and neurite-density (p = 0.041), but not for myelin density, were found.

Three studies compared unscaled T1w/T2w-ratios to histology, all within the cortex [27, 37, 46]. Unscaled T1w/T2w-ratios in histologically confirmed demyelinated areas were statistically significantly lower than in myelinated regions, whereas differences in MTR values were statistically insignificant [27]. Analyzing the relations of unscaled T1w/T2w-ratios with histology within the cortex yielded statistically significant relations only between unscaled T1w/T2w-ratios and dendrite density [46].

Based on different image intensities, Zheng et al. [37] found that using unscaled T1w/T2w-ratios and MTR both yielded a high sensitivity but relatively low specificity and accuracy in detection of demyelination, whereas unscaled T2w image intensities yielded lower sensitivity but higher specificity and accuracy.

4 Discussion

4.1 Interpretation

Since conventional T1w and T2w MRI sequences are broadly available, leveraging their informative wealth beyond visual inspection and volumetry is very attractive. Applying scaling methods before analyses aims to remove the technically induced variance of intensity values while preserving the biological variance. In this systematic review, we focused on studies that avoided brain regions as reference regions because this might include a disease effect in the scaling method (e.g., in inflammatory diseases such as MS or neurodegenerative diseases such as Alzheimer’s).

Variance reduction

Different scaling methods have been suggested, and each of them indeed considerably reduced variance. The reduction of inter-scan variance through intensity scaling is neither surprising nor a proof of validity but a prerequisite for biologically meaningful intensity scaling. The results from Ganzetti et al. [14] showcase the potential of scaling for reducing technical variance across different datasets, and, in a later study [47], their results even indicated that biological variance is preserved. The study by Brown et al. [20] points towards better variance reduction through scaling with NAWM, however, this also comprises the possibility of removed or aggravated biological variance. Hence, variance reduction is a necessary but not a sufficient condition for evaluating intensity scaling methods. In conclusion, sparse evidence suggests that the decrease in inter-scan variance with the preservation of considerable biological variance can be achieved without specific cerebral reference regions. This variance reduction can provide many advantages in studies that need to harmonize multi-subject or multi-center images. Previous studies have investigated and highlighted the importance of intensity scaling in radiomics studies [5, 48]. Hence, radiomics studies dealing with neurodegenerative disease can aim for data harmonization without using cerebral reference regions before calculating radiomics features.

Relation to quantitative imaging and MRI measures related to tissue microstructure

As signal intensities of conventional T1w and T2w images are a composite measure, we did not expect to identify a single definitive (biological) driver of the signal intensity of a conventional sequence. Nonetheless, we considered it possible to observe a coherent pattern with some quantitative measure correlating more strongly to scaled conventional images than others—possibly even providing hints on the main biological drivers of signal intensities in different brain compartments. This was not the case, however. From the perspective of MRI physics, the positive correlation of T1w/T2w-ratio values with quantitative T1 or T2 parameters can be regarded as a truism. Yet, these correlations were found but not as strong and consistent as expected (range of R2: 0.002–0.82). In contrast, we found robust evidence for a correlation of the T1w signal and the T1w/T2w-ratios with MTR (range of R2: 0.25–0.77), which has been validated with histology and was found to correlate with myelin, tissue integrity, and axonal counts [3841]. Surprisingly, only weak (range of R2: 0.05–0.23) or no correlations were reported between scaled T1w, scaled T2w, or T1w/T2w-ratio intensity values and MWF [18, 19] even in WM, although MWF has histologically been validated as a marker of myelin [40, 4244]. Moreover, we found no evidence for the intuitive approach to validate scaling of T1w (or T2w) image intensities through comparison with quantitative T1 (or T2) mapping. We only found studies that investigated correlations between quantitative T1 (or T2) mapping and T1w/T2w-ratios (and not with intensity-scaled T1w or T2w images).

Relation to clinical or demographical data

To explore the clinical correlates that could potentially be associated with intensity changes in scaled conventional T1w and T2w MR images, we summarized the data from 8 studies [18, 20, 25, 26, 28, 29, 34, 45]. Overall, statistically significant correlations with clinical data have been reported, indicating that scaled images can indeed comprise valuable information on brain pathology or development. In line with the results from the direct comparison between scaled and quantitative images, analyses with MTR and with scaled image intensities yielded similar results. However, analyses were conducted for different ROIs within the brain, which hampers the generalizability of results and identification of possible biological proxies.

Relation to histology

No results were available for WM, which contains considerably more axons and myelin than GM. Regarding GM, four studies [27, 37, 45, 46] provided valuable results on the biological information represented by scaled or unscaled T1w/T2w-ratios. Although it has been assumed to be a proxy for myelin in multiple studies, the studies included in this review do not support this hypothesis within the cerebral cortex. This has also previously been commented on [49], and further factors other than myelin seem to interfere. Only one of 4 studies showed a statistically significant relation between myelin and T1w/T2w-ratios in the cortex, but only when comparing demyelinated to non-demyelinated areas [27]. T1w/T2w-ratios seem to be sensitive to various biological properties since they were statistically significantly related to neurite density [45] and to dendrite density [46]. Therefore, and also in line with the relations to quantitative imaging, we believe that the T1w/T2w-ratio requires a new interpretation, similar to the signal of a new MRI sequence. The concept of T1w/T2w-ratio representing a measure of tissue integrity is tempting, but this needs further validation and distinction. In addition, open questions remain, such as the meaning of T1w/T2w-ratios in cases where T1w and T2w image intensities behave similarly (e.g., T1w-high and T2w-high intensities in extracellular meta-hemoglobin from bleedings).

4.2 Limitations

Due to the very heterogeneous nature of scaling and reference methods applied in the included studies, comparing results and combining findings was only possible in descriptive ways. Heterogeneity originated from multiple aspects: 1) studies applied different methods for scaling of conventional T1w and T2w MR images, even for calculating T1w/T2w-ratios different approaches were used; 2) reference methods consisted of either many different quantitative imaging techniques, other scaling methods, or various histology analyses; 3) the ROIs that were investigated varied strongly across studies (tumor, cortex, MS-lesions, WM, subcortical GM, and others); 4) different strategies for (statistical) analyses were applied; 5) most sample sizes were small. Consequently, it was impossible to aggregate results through a meta-analysis. We tried to collect and present results as homogeneously as possible. However, some methodological differences regarding correlation analyses exist. Some studies calculated correlations with quantitative MRI or histology across subjects and regions, and some calculated the correlations across subjects in each region individually. This seemingly little difference may have influenced the results, however. First, including more regions, and, hence, more data points, may lead to increased statistical power; second, if the same subject contributes to more than one data point, the assumptions of Pearson’s correlation are potentially violated.

Finally, the approach of intensity scaling with an extracerebral reference region per se is not without limitations. Even this way, interference with biological effects cannot be ruled out with certainty. For example, considerable changes in the temporal muscle have consistently been found in patients with glioma [50]. Moreover, if established, a scaling method may work reliably only with MRI data acquired at the same scanner with the same protocol.

4.3 Conclusion

We believe it is too early to give definite and detailed recommendations on scaling conventional T1w and T2w MR images. However, the best available evidence is on T1w/T2w ratio imaging. In this regard, we lean towards scaling images before T1w/T2w-ratio calculation in heterogeneous datasets to increase image comparability but not necessarily in homogeneous datasets (e.g., if images were acquired on the same scanner with the same protocol). Regarding scaling methods in general (and before calculating T1w/T2w-ratios), cerebral reference regions can be appropriate if not the whole brain is affected by the state under examination. If the whole brain is likely to be affected, following the suggestions by Ganzetti et al. [14] and using extracerebral reference regions presents an attractive alternative. However, we must emphasize that even extracerebral structures can be affected by the state under examination, as elaborated for glioblastoma, multiple sclerosis, and aging in previous publications [5153], and should therefore be selected with care. Future studies should analyze the effect of the biological factors, such as age or the disease under examination, on the reference region before applying intensity scaling. Scaling methods should be evaluated according to available evidence. We regard correlation with histology or quantitative MRI (or MRI measures related to tissue microstructure) as most desirable, followed by preservation or demonstration of known associations with clinical parameters such as group differences or correlations with clinical scores. In contrast, evidence based on mere variance reduction is precarious as it can go along with removing biologically important variance. In addition, even though Ganzetti et al. [14] reported bias correction and scaling before T1w/T2w-ratio calculation to be helpful for their datasets, this is not necessarily the case for other datasets from different centers and with other MRI scanners, sequence settings, and protocols [54].

In summary, intensity scaling of conventional T1w and T2w MR images without cerebral reference regions is feasible, leading to variance reduction while possibly preserving biologically meaningful information, with the potential to allow for signal quantification as a compound measure of tissue integrity. However, the overall level of evidence is low, with numerous open methodological questions.

Supporting information

S1 Checklist. PRISMA 2020 checklist.

Checklist with items for the PRISMA guideline for reporting systematic reviews.

(PDF)

pone.0298642.s001.pdf (288.6KB, pdf)
S1 File. Supplementary material.

Further information on the systematic review process and the included studies.

(DOCX)

pone.0298642.s002.docx (304.2KB, docx)

Data Availability

All relevant data are within the manuscript and its Supporting information files.

Funding Statement

This study has received funding by a research grant of the National Institutes of Health (grant 1R01NS112161-01) and by a research grant of the German Research Foundation, DFG Priority Programme 2177, Radiomics: Next Generation of Biomedical Imaging (grant 428223038). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Barkovich M. J. and Barkovich A. J., “MR Imaging of Normal Brain Development,” Neuroimaging Clin N Am, vol. 29, no. 3, pp. 325–337, Aug. 2019, doi: 10.1016/j.nic.2019.03.007 [DOI] [PubMed] [Google Scholar]
  • 2.Barkovich A. J., “Concepts of Myelin and Myelination in Neuroradiology,” AJNR Am J Neuroradiol, vol. 21, no. 6, p. 1099, 2000, Accessed: Mar. 27, 2023. [Online]. Available: /pmc/articles/PMC7973874/ [PMC free article] [PubMed] [Google Scholar]
  • 3.Fang M. et al., “Myelination of the Pig’s Brain: A Correlated MRI and Histological Study,” Neurosignals, vol. 14, no. 3, pp. 102–108, Jul. 2005, doi: 10.1159/000086292 [DOI] [PubMed] [Google Scholar]
  • 4.Ashburner J. and Friston K. J., “Unified segmentation,” Neuroimage, vol. 26, no. 3, pp. 839–851, Jul. 2005, doi: 10.1016/j.neuroimage.2005.02.018 [DOI] [PubMed] [Google Scholar]
  • 5.Carré A. et al., “Standardization of brain MR images across machines and protocols: bridging the gap for MRI-based radiomics,” Sci Rep, vol. 10, no. 1, Dec. 2020, doi: 10.1038/s41598-020-69298-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Salome P. et al., “MR Intensity Normalization Methods Impact Sequence Specific Radiomics Prognostic Model Performance in Primary and Recurrent High-Grade Glioma,” Cancers (Basel), vol. 15, no. 3, Feb. 2023, doi: 10.3390/cancers15030965 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Shinohara R. T. et al., “Statistical normalization techniques for magnetic resonance imaging,” Neuroimage Clin, vol. 6, pp. 9–19, Jan. 2014, doi: 10.1016/j.nicl.2014.08.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Dadar M., Narayanan S., Arnold D. L., Collins D. L., and Maranzano J., “Conversion of diffusely abnormal white matter to focal lesions is linked to progression in secondary progressive multiple sclerosis,” Multiple Sclerosis Journal, vol. 27, no. 2, pp. 208–219, Feb. 2021, doi: 10.1177/1352458520912172 [DOI] [PubMed] [Google Scholar]
  • 9.De Groot M. et al., “Changes in normal-appearing white matter precede development of white matter lesions,” Stroke, vol. 44, no. 4, pp. 1037–1042, Apr. 2013, doi: 10.1161/STROKEAHA.112.680223 [DOI] [PubMed] [Google Scholar]
  • 10.Maranzano J., Dadar M., Zhernovaia M., Arnold D. L., Collins D. L., and Narayanan S., “Automated separation of diffusely abnormal white matter from focal white matter lesions on MRI in multiple sclerosis,” Neuroimage, vol. 213, p. 116690, Jun. 2020, doi: 10.1016/j.neuroimage.2020.116690 [DOI] [PubMed] [Google Scholar]
  • 11.Kutzelnigg A. et al., “Cortical demyelination and diffuse white matter injury in multiple sclerosis,” Brain, vol. 128, no. 11, pp. 2705–2712, 2005, doi: 10.1093/brain/awh641 [DOI] [PubMed] [Google Scholar]
  • 12.Glasser M. F. and van Essen D. C., “Mapping Human Cortical Areas In Vivo Based on Myelin Content as Revealed by T1- and T2-Weighted MRI,” The Journal of Neuroscience, vol. 31, no. 32, p. 11597, Aug. 2011, doi: 10.1523/JNEUROSCI.2180-11.2011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Glasser M. F. et al., “Empirical transmit field bias correction of T1w/T2w myelin maps,” Neuroimage, vol. 258, Sep. 2022, doi: 10.1016/j.neuroimage.2022.119360 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ganzetti M., Wenderoth N., and Mantini D., “Whole brain myelin mapping using T1- and T2-weighted MR imaging data,” Front Hum Neurosci, vol. 8, no. SEP, Sep. 2014, doi: 10.3389/fnhum.2014.00671 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Page M. J. et al., “The PRISMA 2020 statement: An updated guideline for reporting systematic reviews,” The BMJ, vol. 372. BMJ Publishing Group, Mar. 29, 2021. doi: 10.1136/bmj.n71 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Wiltgen T. and Mühlau M., “Extracerebral reference regions for intensity scaling of conventional MR images: A systematic review.” PROSPERO, 2022. [Online]. Available: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022303699 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Loizou C. P., Pantziaris M., Seimenis I., and Pattichis C. S., “Brain MR Image Normalization in Texture Analysis of Multiple Sclerosis,” [IEEE; ], 2009. [Google Scholar]
  • 18.Gilmore J. H. et al., “Early Postnatal Development of Corpus Callosum and Corticospinal White Matter Assessed with Quantitative Tractography,” American Journal of Neuroradiology, vol. 28, no. 9, 2007, doi: 10.3174/ajnr.a0751 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Uddin M. N., Figley T. D., Marrie R. A., and Figley C. R., “Can T1w/T2w ratio be used as a myelin-specific measure in subcortical structures? Comparisons between FSE-based T1w/T2w ratios, GRASE-based T1w/T2w ratios and multi-echo GRASE-based myelin water fractions,” NMR Biomed, vol. 31, no. 3, Mar. 2018, doi: 10.1002/nbm.3868 [DOI] [PubMed] [Google Scholar]
  • 20.Brown R. A. et al., “Deep learning segmentation of orbital fat to calibrate conventional MRI for longitudinal studies,” Neuroimage, vol. 208, Mar. 2020, doi: 10.1016/j.neuroimage.2019.116442 [DOI] [PubMed] [Google Scholar]
  • 21.Soun J. E., Liu M. Z., Cauley K. A., and Grinband J., “Evaluation of neonatal brain myelination using the T1- and T2-weighted MRI ratio,” Journal of Magnetic Resonance Imaging, vol. 46, no. 3, pp. 690–696, Sep. 2017, doi: 10.1002/jmri.25570 [DOI] [PubMed] [Google Scholar]
  • 22.Cappelle S. et al., “T1w/FLAIR ratio standardization as a myelin marker in MS patients,” Neuroimage Clin, vol. 36, p. 103248, Jan. 2022, doi: 10.1016/j.nicl.2022.103248 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Arshad M., Stanley J. A., and Raz N., “Test–retest reliability and concurrent validity of in vivo myelin content indices: Myelin water fraction and calibrated T1w/T2w image ratio,” Hum Brain Mapp, vol. 38, no. 4, pp. 1780–1790, Apr. 2017, doi: 10.1002/hbm.23481 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Hagiwara A. et al., “Myelin Measurement: Comparison between Simultaneous Tissue Relaxometry, Magnetization Transfer Saturation Index, and T1w/T2w Ratio Methods,” Sci Rep, vol. 8, no. 1, Dec. 2018, doi: 10.1038/s41598-018-28852-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Hannoun S. et al., “T1/T2 ratio: A quantitative sensitive marker of brain tissue integrity in multiple sclerosis,” Journal of Neuroimaging, vol. 32, no. 2, pp. 328–336, Mar. 2022, doi: 10.1111/jon.12943 [DOI] [PubMed] [Google Scholar]
  • 26.Luo X. et al., “Application of T1-/T2-Weighted Ratio Mapping to Elucidate Intracortical Demyelination Process in the Alzheimer’s Disease Continuum,” Front Neurosci, vol. 13, p. 904, Sep. 2019, doi: 10.3389/fnins.2019.00904 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Nakamura K., Chen J. T., Ontaneda D., Fox R. J., and Trapp B. D., “T1-/T2-weighted ratio differs in demyelinated cortex in multiple sclerosis,” Ann Neurol, vol. 82, no. 4, pp. 635–639, Oct. 2017, doi: 10.1002/ana.25019 [DOI] [PubMed] [Google Scholar]
  • 28.Pareto D. et al., “Ratio of T1-Weighted to T2-Weighted Signal Intensity as a Measure of Tissue Integrity: Comparison with Magnetization Transfer Ratio in Patients with Multiple Sclerosis,” American Journal of Neuroradiology, vol. 41, no. 3, pp. 461–463, Mar. 2020, doi: 10.3174/ajnr.A6481 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Saccenti L. et al., “Myelin Measurement Using Quantitative Magnetic Resonance Imaging: A Correlation Study Comparing Various Imaging Techniques in Patients with Multiple Sclerosis,” Cells, vol. 9, no. 2, Feb. 2020, doi: 10.3390/cells9020393 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Sanada T. et al., “Correlation of T1- to T2-weighted signal intensity ratio with T1- and T2-relaxation time and IDH mutation status in glioma,” Scientific Reports 2022 12:1, vol. 12, no. 1, pp. 1–9, Nov. 2022, doi: 10.1038/s41598-022-23527-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Shams Z., Norris D. G., and Marques J. P., “A comparison of in vivo MRI based cortical myelin mapping using T1w/T2w and R1 mapping at 3T,” PLoS One, vol. 14, no. 7, Jul. 2019, doi: 10.1371/journal.pone.0218089 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Shim J. M., Cho S. E., Kang S. G., and Kang C. K., “Quantitative myelin-related maps from R1 and T2* ratio images using a single ME-MP2RAGE sequence in 7T MRI,” Front Neuroanat, vol. 16, p. 74, Aug. 2022, doi: 10.3389/FNANA.2022.950650/BIBTEX [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Uddin M. N., Figley T. D., Solar K. G., Shatil A. S., and Figley C. R., “Comparisons between multi-component myelin water fraction, T1w/T2w ratio, and diffusion tensor imaging measures in healthy human brain structures,” Sci Rep, vol. 9, no. 1, Dec. 2019, doi: 10.1038/s41598-019-39199-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Vandewouw M. M., Young J. M., Shroff M. M., Taylor M. J., and Sled J. G., “Altered myelin maturation in four year old children born very preterm,” Neuroimage Clin, vol. 21, Jan. 2019, doi: 10.1016/j.nicl.2018.101635 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Yamamoto S. et al., “Prediction and Visualization of Non-Enhancing Tumor in Glioblastoma via T1w/T2w-Ratio Map,” Brain Sci, vol. 12, no. 1, Jan. 2022, doi: 10.3390/brainsci12010099 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Yasuno F. et al., “Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects,” Neuroimage Clin, vol. 13, pp. 209–214, 2017, doi: 10.1016/j.nicl.2016.11.029 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Zheng Y. et al., “Sensitivity of T1/T2-weighted ratio in detection of cortical demyelination is similar to magnetization transfer ratio using post-mortem MRI,” Mult Scler, vol. 28, no. 2, p. 198, Feb. 2022, doi: 10.1177/13524585211014760 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Schmierer K., Scaravilli F., Altmann D. R., Barker G. J., and Miller D. H., “Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain,” Ann Neurol, vol. 56, no. 3, pp. 407–415, Sep. 2004, doi: 10.1002/ana.20202 [DOI] [PubMed] [Google Scholar]
  • 39.Schmierer K. et al., “Quantitative magnetic resonance of postmortem multiple sclerosis brain before and after fixation,” Magn Reson Med, vol. 59, no. 2, pp. 268–277, 2008, doi: 10.1002/mrm.21487 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Laule C. et al., “Magnetic resonance imaging of myelin,” Neurotherapeutics 2007 4:3, vol. 4, no. 3, pp. 460–484, Jul. 2007, doi: 10.1016/J.NURT.2007.05.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Tien-Hsiang Chen J. et al., “Clinically feasible MTR is sensitive to cortical demyelination in MS,” 2012, Accessed: Mar. 08, 2023. [Online]. Available: doi: 10.1212/WNL.0b013e31827deb99 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Laule C., Kozlowski P., Leung E., Li D. K. B., MacKay A. L., and Moore G. R. W., “Myelin water imaging of multiple sclerosis at 7 T: correlations with histopathology,” Neuroimage, vol. 40, no. 4, pp. 1575–1580, May 2008, doi: 10.1016/j.neuroimage.2007.12.008 [DOI] [PubMed] [Google Scholar]
  • 43.Laule C. et al., “Myelin water imaging in multiple sclerosis: Quantitative correlations with histopathology,” Multiple Sclerosis, vol. 12, no. 6, pp. 747–753, Dec. 2006, doi: 10.1177/1352458506070928 [DOI] [PubMed] [Google Scholar]
  • 44.Webb S., Munro C. A., Midha R., and Stanisz G. J., “Is multicomponent T2 a good measure of myelin content in peripheral nerve?,” Magn Reson Med, vol. 49, no. 4, pp. 638–645, Apr. 2003, doi: 10.1002/mrm.10411 [DOI] [PubMed] [Google Scholar]
  • 45.Preziosa P. et al., “Neurite density explains cortical T1-weighted/T2-weighted ratio in multiple sclerosis,” J Neurol Neurosurg Psychiatry, vol. 92, no. 7, pp. 790–792, Jul. 2021, doi: 10.1136/jnnp-2020-324391 [DOI] [PubMed] [Google Scholar]
  • 46.Righart R. et al., “Cortical pathology in multiple sclerosis detected by the T1/T2-weighted ratio from routine magnetic resonance imaging,” Ann Neurol, vol. 82, no. 4, pp. 519–529, Oct. 2017, doi: 10.1002/ana.25020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Ganzetti M., Wenderoth N., and Mantini D., “Mapping pathological changes in brain structure by combining T1- and T2-weighted MR imaging data,” Neuroradiology, vol. 57, no. 9, pp. 917–928, Sep. 2015, doi: 10.1007/s00234-015-1550-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Foltyn-Dumitru M. et al., “Impact of signal intensity normalization of MRI on the generalizability of radiomic-based prediction of molecular glioma subtypes,” Eur Radiol, 2023, doi: 10.1007/s00330-023-10034-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Mühlau M., “T1/T2-weighted ratio is a surrogate marker of demyelination in multiple sclerosis: No,” 10.1177/13524585211063622, vol. 28, no. 3, pp. 355–356, Jan. 2022, [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Sadhwani N., Aggarwal A., Mishra A., and Garg K., “Temporal muscle thickness as an independent prognostic marker in glioblastoma patients—a systematic review and meta-analysis,” Neurosurgical Review, vol. 45, no. 6. Springer Science and Business Media Deutschland GmbH, pp. 3619–3628, Dec. 01, 2022. doi: 10.1007/s10143-022-01892-3 [DOI] [PubMed] [Google Scholar]
  • 51.Sadhwani N., Aggarwal A., Mishra A., and Garg K., “Temporal muscle thickness as an independent prognostic marker in glioblastoma patients—a systematic review and meta-analysis,” Neurosurgical Review, vol. 45, no. 6. Springer Science and Business Media Deutschland GmbH, pp. 3619–3628, Dec. 01, 2022. doi: 10.1007/s10143-022-01892-3 [DOI] [PubMed] [Google Scholar]
  • 52.Haider L. et al., “The relation of sarcopenia and disability in multiple sclerosis,” Mult Scler Relat Disord, vol. 77, Sep. 2023, doi: 10.1016/j.msard.2023.104855 [DOI] [PubMed] [Google Scholar]
  • 53.Streckenbach F. et al., “Age-related changes of the human crystalline lens on high-spatial resolution three-dimensional T1-weighted brain magnetic resonance images in vivo,” Invest Ophthalmol Vis Sci, vol. 61, no. 14, Dec. 2020, doi: 10.1167/iovs.61.14.7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Nerland S. et al., “Multisite reproducibility and test-retest reliability of the T1w/T2w-ratio: A comparison of processing methods,” Neuroimage, vol. 245, Dec. 2021, doi: 10.1016/j.neuroimage.2021.118709 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Md Nasir Uddin

8 Jan 2024

PONE-D-23-37143Intensity scaling of conventional brain magnetic resonance images avoiding cerebral reference regions: A systematic reviewPLOS ONE

Dear Dr. Wiltgen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.  Reviewer 2 has raised significant concerns. It is recommended to incorporate additional analyses and clarifications to get the manuscript accepted.  

Please submit your revised manuscript by Feb 22 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Md Nasir Uddin, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

"This study has received funding by a research grant of the National Institutes of Health (grant 1R01NS112161-01) and by a research grant of the German Research Foundation, DFG Priority Programme 2177, Radiomics: Next Generation of Biomedical Imaging (grant 428223038)"

  

Please state what role the funders took in the study.  If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

3. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files.]

Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition).

For example, authors should submit the following data:

- The values behind the means, standard deviations and other measures reported;

- The values used to build graphs;

- The points extracted from images for analysis.

Authors do not need to submit their entire data set if only a portion of the data was used in the reported study.

If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories.

If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access.

4. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Your article demonstrates a comprehensive understanding of the subject matter and presents valuable insights. The thorough research and clear presentation make it a strong contribution to the academic community.

Reviewer #2: The goal of this study was to review approaches for intensity scaling of T1w and T2w images. The authors focused on an interesting subcategory of methods that either utilize extracerebral reference regions or take T1w/T2w ratios. Based on the manuscript, the rationale of this review is 1) to examine the efficacy of these reviewed method compared to other scaling methods, and 2) to explore potential biophysical information contained in scaled T1w and T2w images.

This study has a number of strengths, including the review methodology and the thorough presentation of data. The manuscript itself is also very well written. Nonetheless, I believe the paper could benefit from further discussion of the implications of their findings, and there are a few areas in which more clarification is needed. These concerns are detailed below.

1. The inclusion of T1w/T2w ratio in this review is interesting, but it’s apparently a different approach compared to intensity scaling based on reference regions or histogram matching. I therefore think a dedicated paragraph is needed to justify this rationale and introduce commonly used terms in the literature. In particular, intensity normalization vs. intensity scaling: some people use them interchangeably, but others may have very different definitions (my impression is that scaling involves a linear transformation, such as the Ganzetti method, while intensity normalization include histogram matching and local bias correction methods).

2. Following the previous comment, taking the ratio of T1w over T2w images in my opinion serves as a bias correction (canceling out B1- field). As the authors briefly mentioned in the introduction that “An essential prerequisite is the bias field correction” and scaling is done on “conventional bias-corrected MRI”, I think more introduction is needed about bias correction and its relationship with intensity scaling in image processing. For instance, many bias correction methods exist targeting different kind of bias fields (e.g., take T1w/T2w ratio, estimate local intensity inhomogeneities, apply field maps). This will help further clarify the range of current review.

3. When referring to the Sham 2019 article, the authors present the correlation R square between R1 and “raw T1w/T2w” to be 0.8 (line 288). However, this is the results for T1w/T2w that went through additional bias correction using the group average myelin map on Conte69 mesh. The “regular” bias corrected T1w/T2w (which may be more comparable to the other T1w/T2w ratios reviewed here?) has a correlation R square of 0.74 with R1. Please clarify the definition of “raw” when describing these images.

4. A brief mention of the specificity of the quantitative measures included here would be helpful. Diffusion measures are sensitive to microstructural changes but are not specific. For myelin estimate, I think MWF should be the most robust one out of those included here. Also, I don’t think diffusion metrics and MTR are normally considered as quantitative (maybe single them out as measures related to microstructure/tissue property?).

5. In terms of the correlation with quantitative MRI or histology, I think the discussion should also point out potential biases from correlation approaches. For example, most studies used an across-region/voxel correlation (each dot in the scatter plot represents one region/voxel from one subject, number of datapoint = N(subject) * N(region)). However, some reviewed here, such as Hannoun 2022, did the correlation across subject in each region separately (number of datapoint = N(subject)). Including more datapoint increases statistical power and may have smaller r coefficient to come up as significant. Moreover, when the same subject contributes to more than one datapoint in the correlation, one may also argue that the data included are not independent, therefore violating the assumptions of Pearson’s correlation.

6. Another question not explicitly answered is whether using extracerebral reference regions really differs from or outperforms cerebral ref regions. Both may artificially affect meaningful between-subject variation, and the signal intensity can change with biological factors and pathology (this study shows T1w signal of the eyeball is also correlated with age https://www.ncbi.nlm.nih.gov/pubmed/33270843). Then do the findings of this review support the use of extracerebral ref regions over cerebral ones?

7. Lastly, the discussion would also benefit from an evaluation of approaches for checking the quality of a given scaling method. Is variance reduction the ultimate criterion of a good scaling? Or strong correlation with histology/quantitative MRI, preservation of patient vs. control differences, or elimination of site/batch effect?

Minor comments:

1. The phrasing in the abstract and introduction can be misleading. The authors state that they “summarize approaches for intensity scaling of conventional brain MRI that avoid reference regions within the brain”, which gave me the impression that this study only reviews methods that don’t involve reference regions. Conventional brain MRI is also non-specific: FLAIR and proton density are typically acquired for clinical scans but not examined here. The authors could clarify this by using more specific descriptions, like: “summarize approaches for intensity scaling of T1w and T2w images that utilize extracerebral reference regions”.

2. Table 4. Gilmore (2007) study on scaled T1w correlation with MD: better have the number right aligned to be consistent with other positive correlations.

3. Table 4. Gilmore (2007) on scaled T2w correlation with FA and MD: while the r coefficients are not available, it may be useful to indicate the direction of these correlations.

4. Line 398: T1-weighted -> T1w (abbreviation introduced previously)

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Mahdi Mohammadi

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2024 Mar 14;19(3):e0298642. doi: 10.1371/journal.pone.0298642.r002

Author response to Decision Letter 0


22 Jan 2024

Dear Dr. Udding

Dear Reviewers:

On behalf of all authors, we thank you for your positive comments. We feel we can address the critique (only raised by Reviewer 2) adequately. We hope very much that you find our new version improved so that it can be further considered for publication. We resubmitted our revised manuscript in two versions, one without and one with the relevant changes marked. Please note that line numbers in the rebuttal letter refer to the clean version.

Please find below our point-by-point response.

Kind regards

Tun Wiltgen and Mark Mühlau

Point-by-point response:

Major concerns:

‘1. The inclusion of T1w/T2w ratio in this review is interesting, but it’s apparently a different approach compared to intensity scaling based on reference regions or histogram matching. I therefore think a dedicated paragraph is needed to justify this rationale and introduce commonly used terms in the literature. In particular, intensity normalization vs. intensity scaling: some people use them interchangeably, but others may have very different definitions (my impression is that scaling involves a linear transformation, such as the Ganzetti method, while intensity normalization include histogram matching and local bias correction methods).

2. Following the previous comment, taking the ratio of T1w over T2w images in my opinion serves as a bias correction (canceling out B1- field). As the authors briefly mentioned in the introduction that “An essential prerequisite is the bias field correction” and scaling is done on “conventional bias-corrected MRI”, I think more introduction is needed about bias correction and its relationship with intensity scaling in image processing. For instance, many bias correction methods exist targeting different kind of bias fields (e.g., take T1w/T2w ratio, estimate local intensity inhomogeneities, apply field maps). This will help further clarify the range of current review.’

We have now further described the relationship of bias field correction with intensity scaling in the introduction (lines 56-60):

“Particularly, in studies investigating image intensities, local intensity inhomogeneities induced by transmit and receiver field inhomogeneities should be removed through bias field correction because observed signal variations (after intensity scaling) should arise from biological differences of tissues rather than from technical factors.”

We agree that the T1w/T2w-ratio constitutes a different rationale and exploits a different principle than intensity scaling based on reference regions. While we had described the basic ideas of intensity scaling, we now see that the introduction needs clarification on why we included the T1w/T2w-ratio method in our review. We have now added a paragraph in the introduction dedicated explicitly to the T1w/T2w-ratio and moved parts of the last introduction paragraph to this new paragraph (lines 77-92):

“Originally, we planned to include studies using an extracerebral reference region for intensity scaling. However, the literature search revealed many studies that applied intensity scaling without reference regions but by using the T1w/T2w-ratio introduced by Glasser and van Essen [12]. We found several versions of this approach, either with or without prior scaling of the T1w and T2w images with extracerebral reference regions. Hence, we decided to extend the scope of our review and included studies using the T1w/T2w-ratio with or without prior intensity scaling if the validity of the approach was investigated. Calculation of T1w/T2w-ratio images does not require a reference region, and by dividing T1w by T2w image intensities, it is possible to obtain images with new contrasts. Most of these studies assume that the ratio of T1w and T2w images reflects myelin [12], since voxels in highly myelinated regions have high-intensity values in T1w images but low-intensity values in T2w images, but did not evaluate the method further. In addition, it has been hypothesized that T1w and T2w images are similarly affected by technical artifacts, such as bias field, and that, therefore, by calculating the ratio of T1w and T2w images, these technical artifacts are canceled out at the same time [12], [13], [14]. Yet, this assumption does not seem to be true for all MRI scanners; in consequence, some authors suggested separate scaling of T1w and T2w images before calculating the ratio of the two [14].”

During the process of this systematic review, we also found that the interchangeable use of the terms scaling and normalization can be very confusing. In our experience, intensity normalization is often used for z-score normalization (subtracting the mean and dividing by the standard deviation) or, as the reviewer mentioned, for histogram matching. In this systematic review, however, we focus on intensity scaling (i.e., translating intensity values by a determined algebraic rule, usually a linear transformation). To prevent confusion for the reader, we avoid the term intensity normalization in the text completely. It is only given in the keywords (as some authors use intensity normalization and intensity scaling interchangeably).

‘3. When referring to the Sham 2019 article, the authors present the correlation R square between R1 and “raw T1w/T2w” to be 0.8 (line 288). However, this is the results for T1w/T2w that went through additional bias correction using the group average myelin map on Conte69 mesh. The “regular” bias corrected T1w/T2w (which may be more comparable to the other T1w/T2w ratios reviewed here?) has a correlation R square of 0.74 with R1. Please clarify the definition of “raw” when describing these images.’

We agree that we should provide the data on the T1w/T2w-ratio without additional bias correction. We have now changed the value from 0.8 to 0.74.

Table 3 in S2 Supplementary Material indicates whether and which bias field correction has been applied to the images for each study.

In addition, we have now changed the terminology (from “raw” to “unscaled” but the changes are not marked in revised manuscript) for clarity as we think intuitively “raw” should refer to unprocessed images (as output by the scanner to the picture archiving system). We now simply refer to unscaled (but possibly bias-corrected) images as “unscaled” images, which we have now specified in section 3.2 (lines 164-167):

“We refer to “unscaled” ratios whenever image intensities have not been scaled. However, images used to calculate the ratio may have undergone bias field correction as in most studies using T1w/T2w-ratios (Table 3 in S2 Supplementary Material).”

We have also changed the terminology from “raw” to “unscaled” in the supplementary material.

‘4. A brief mention of the specificity of the quantitative measures included here would be helpful. Diffusion measures are sensitive to microstructural changes but are not specific. For myelin estimate, I think MWF should be the most robust one out of those included here. Also, I don’t think diffusion metrics and MTR are normally considered as quantitative (maybe single them out as measures related to microstructure/tissue property?).’

We added information on the diffusion measures (lines 291-293):

“The correlations with DWI metrics, known to be sensitive to microstructural changes, were statistically insignificant, except for the correlation between mean diffusivity (MD) and scaled T1w …”.

We agree that MWF should be the most robust myelin estimate. We had emphasized the relation of MWF to myelin in line 289-290 and in lines 410-412.

In section 2, we have now specified that we also consider MRI measures related to tissue microstructure (such as MTR), and we have now renamed the section, table, and figure titles so that they include: “MRI measures related to tissue microstructure”. For shortness of wording, we still refer only to quantitative MRI but we have now added the following in section 3.3.2 (lines 241-243):

“Although we are aware that they are not fully quantitative, we refer to the “MRI measures related to tissue microstructure”, such as magnetization transfer ratio (MTR) or diffusion-weighted imaging (DWI), as “quantitative imaging” for readability.”

‘5. In terms of the correlation with quantitative MRI or histology, I think the discussion should also point out potential biases from correlation approaches. For example, most studies used an across-region/voxel correlation (each dot in the scatter plot represents one region/voxel from one subject, number of datapoint = N(subject) * N(region)). However, some reviewed here, such as Hannoun 2022, did the correlation across subject in each region separately (number of datapoint = N(subject)). Including more datapoint increases statistical power and may have smaller r coefficient to come up as significant. Moreover, when the same subject contributes to more than one datapoint in the correlation, one may also argue that the data included are not independent, therefore violating the assumptions of Pearson’s correlation.’

We fully agree. Yet, this problem does not directly influence our findings as we could only review and summarize data descriptively. We now mention this issue in the discussion (lines 451-458):

“We tried to collect and present results as homogeneously as possible. However, some methodological differences regarding correlation analyses exist. Some studies calculated correlations with quantitative MRI or histology across subjects and regions, and some calculated the correlations across subjects in each region individually. This seemingly little difference may have influenced the results, however. First, including more regions, and, hence, more data points, may lead to increased statistical power; second, if the same subject contributes to more than one data point, the assumptions of Pearson’s correlation are potentially violated.”

‘6. Another question not explicitly answered is whether using extracerebral reference regions really differs from or outperforms cerebral ref regions. Both may artificially affect meaningful between-subject variation, and the signal intensity can change with biological factors and pathology (this study shows T1w signal of the eyeball is also correlated with age https://www.ncbi.nlm.nih.gov/pubmed/33270843). Then do the findings of this review support the use of extracerebral ref regions over cerebral ones?’

We had addressed this in the conclusion. Again, we must emphasize that we do NOT believe that scaling with extracerebral reference regions is always the better choice. A huge caveat is that even the extracerebral region can be affected by neuropsychiatric diseases. In the worst case, this association may be unknown! In the discussion (lines 473-475), we had addressed this issue with the example of the temporal muscle; we have now added the reviewer’s impressive example of the eyeball by Streckenbach et al. (PMID 33270843), which we had not known.

‘7. Lastly, the discussion would also benefit from an evaluation of approaches for checking the quality of a given scaling method. Is variance reduction the ultimate criterion of a good scaling? Or strong correlation with histology/quantitative MRI, preservation of patient vs. control differences, or elimination of site/batch effect?’

We fully agree. In the discussion, we mentioned variance reduction as a criterion for intensity scaling, and we concluded that maximizing variance reduction can be misleading since biologically induced variance might also be removed. Elimination of site/batch effect can also be a reasonable goal, but good results in this regard do not necessarily imply good intensity scaling since it might also lead to the removal of biologically induced variance. We now elaborate more clearly that we rate variance reduction as a necessary but not a sufficient condition for valid intensity scaling (lines 390-391):

“Hence, variance reduction is a necessary but not a sufficient condition for evaluating intensity scaling methods.”

Moreover, we also see an important role in correlation with histology, quantitative MRI (and MRI-measures related to microstructure), and preservation of associations with clinical parameters (e.g., group differences and correlations with clinical scores). The same applies to the elimination of site/batch effects, which was not investigated in the studies we identified, however. We now mention these opportunities in the discussion (lines 477-482):

“Scaling methods should be evaluated according to available evidence. We regard correlation with histology or quantitative MRI (or MRI measures related to tissue microstructure) as most desirable, followed by preservation or demonstration of known associations with clinical parameters such as group differences or correlations with clinical scores. In contrast, evidence based on mere variance reduction is precarious as it can go along with removing biologically important variance.”

Minor concerns:

‘1. The phrasing in the abstract and introduction can be misleading. The authors state that they “summarize approaches for intensity scaling of conventional brain MRI that avoid reference regions within the brain”, which gave me the impression that this study only reviews methods that don’t involve reference regions. Conventional brain MRI is also non-specific: FLAIR and proton density are typically acquired for clinical scans but not examined here. The authors could clarify this by using more specific descriptions, like: “summarize approaches for intensity scaling of T1w and T2w images that utilize extracerebral reference regions”.’

We, in part, agree. We now use the term T1w and T2w images instead of conventional MRI. Regarding the term ‘extracerebral reference region,’ we see the problem that it does not really cover T1w/T2w-ratio images. Therefore, we now write ‘intensity scaling of conventional T1-weighted (w) and T2w brain MRI avoiding reference regions within the brain’ (line 21).

‘2. Table 4. Gilmore (2007) study on scaled T1w correlation with MD: better have the number right aligned to be consistent with other positive correlations.’

The correlation of T1w with MD is negative, which is why we had aligned the number on the left side. The trend of the correlation can be deduced from Fig 5 in the supplementary material of Gilomore’s publication.

‘3. Table 4. Gilmore (2007) on scaled T2w correlation with FA and MD: while the r coefficients are not available, it may be useful to indicate the direction of these correlations.’

We have now added “positive” or “negative” in the “Results” column.

‘4. Line 398: T1-weighted -> T1w (abbreviation introduced previously)’

We have now changed T1-weighted to T1w.

Attachment

Submitted filename: Response_to_Reviewers.pdf

pone.0298642.s003.pdf (409.3KB, pdf)

Decision Letter 1

Md Nasir Uddin

29 Jan 2024

Intensity scaling of conventional brain magnetic resonance images avoiding cerebral reference regions: A systematic review

PONE-D-23-37143R1

Dear Dr. Wiltgen,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. 

Authors are encouraged to address the minor comments provided by reviewer 2. 

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Md Nasir Uddin, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: (No Response)

Reviewer #2: The authors have suitably addressed my previous comments. Based on their changes, I have only one minor comment that I think might benefit the manuscript:

Revised line 87-92: please make clear that by taking T1w/T2w ratio, only the receiver bias field (B1-) can be exactly canceled out, given that the head position is not changed. B1+ fields are different in T1w and T2w images due to pulse differences and these inhomogeneities in extreme situations (like in 7T) may even affect image contrast (e.g., in a single image, GM/WM contrast is higher in the center and lower in peripheral areas of FOV. This is also why in my opinion integrating data acquired with different protocol is probably never feasible/accurate no matter which scaling method is used, but this may be outside the scope of current discussion).

Thank you to the authors for looking into this interesting topic and I look forward to citing this in the future.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Mahdi Mohammadi

Reviewer #2: No

**********

Acceptance letter

Md Nasir Uddin

12 Feb 2024

PONE-D-23-37143R1

PLOS ONE

Dear Dr. Wiltgen,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Md Nasir Uddin

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Checklist. PRISMA 2020 checklist.

    Checklist with items for the PRISMA guideline for reporting systematic reviews.

    (PDF)

    pone.0298642.s001.pdf (288.6KB, pdf)
    S1 File. Supplementary material.

    Further information on the systematic review process and the included studies.

    (DOCX)

    pone.0298642.s002.docx (304.2KB, docx)
    Attachment

    Submitted filename: Response_to_Reviewers.pdf

    pone.0298642.s003.pdf (409.3KB, pdf)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting information files.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES